Compare Cipla with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs ALKEM LABORATORIES - Comparison Results

CIPLA     Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA ALKEM LABORATORIES CIPLA/
ALKEM LABORATORIES
 
P/E (TTM) x 23.8 - - View Chart
P/BV x 2.4 7.0 34.8% View Chart
Dividend Yield % 0.7 0.6 106.7%  

Financials

 CIPLA   ALKEM LABORATORIES
EQUITY SHARE DATA
    CIPLA
Mar-19
ALKEM LABORATORIES
Mar-16
CIPLA/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs6781,589 42.7%   
Low Rs4841,232 39.3%   
Sales per share (Unadj.) Rs198.2417.5 47.5%  
Earnings per share (Unadj.) Rs18.556.3 32.9%  
Cash flow per share (Unadj.) Rs35.064.7 54.1%  
Dividends per share (Unadj.) Rs3.0012.70 23.6%  
Dividend yield (eoy) %0.50.9 57.4%  
Book value per share (Unadj.) Rs186.3292.9 63.6%  
Shares outstanding (eoy) m805.70119.57 673.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.93.4 86.7%   
Avg P/E ratio x31.425.1 125.2%  
P/CF ratio (eoy) x16.621.8 76.2%  
Price / Book Value ratio x3.14.8 64.7%  
Dividend payout %16.222.6 71.8%   
Avg Mkt Cap Rs m468,031168,653 277.5%   
No. of employees `00022.6NA-   
Total wages/salary Rs m28,5659,171 311.5%   
Avg. sales/employee Rs Th7,053.1NM-  
Avg. wages/employee Rs Th1,261.5NM-  
Avg. net profit/employee Rs Th659.1NM-  
INCOME DATA
Net Sales Rs m159,71049,915 320.0%  
Other income Rs m4,7661,645 289.7%   
Total revenues Rs m164,47551,561 319.0%   
Gross profit Rs m30,9738,482 365.1%  
Depreciation Rs m13,2631,006 1,318.7%   
Interest Rs m1,684671 251.2%   
Profit before tax Rs m20,7918,451 246.0%   
Minority Interest Rs m-172-114 150.9%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6951,606 354.6%   
Profit after tax Rs m14,9246,731 221.7%  
Gross profit margin %19.417.0 114.1%  
Effective tax rate %27.419.0 144.1%   
Net profit margin %9.313.5 69.3%  
BALANCE SHEET DATA
Current assets Rs m124,26627,062 459.2%   
Current liabilities Rs m37,71515,324 246.1%   
Net working cap to sales %54.223.5 230.5%  
Current ratio x3.31.8 186.6%  
Inventory Days Days9167 136.3%  
Debtors Days Days9541 229.8%  
Net fixed assets Rs m105,19012,610 834.2%   
Share capital Rs m1,611239 673.9%   
"Free" reserves Rs m148,51134,490 430.6%   
Net worth Rs m150,12335,027 428.6%   
Long term debt Rs m38,3011,212 3,161.2%   
Total assets Rs m239,63354,387 440.6%  
Interest coverage x13.313.6 98.1%   
Debt to equity ratio x0.30 737.6%  
Sales to assets ratio x0.70.9 72.6%   
Return on assets %6.913.6 50.9%  
Return on equity %9.919.2 51.7%  
Return on capital %11.824.9 47.6%  
Exports to sales %34.712.9 268.1%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs m55,4196,461 857.7%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m57,4106,563 874.7%   
Fx outflow Rs m19,0413,012 632.2%   
Net fx Rs m38,3683,552 1,080.3%   
CASH FLOW
From Operations Rs m16,9117,259 233.0%  
From Investments Rs m-16,6871,864 -895.1%  
From Financial Activity Rs m-3,487-9,273 37.6%  
Net Cashflow Rs m-3,451-150 2,300.7%  

Share Holding

Indian Promoters % 16.0 66.9 23.9%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 33.1 36.9%  
FIIs % 23.7 0.0 -  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 0.0 -  
Shareholders   161,166 68,381 235.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  PFIZER  

Compare CIPLA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

CIPLA 2018-19 Annual Report Analysis (Annual Result Update)

Sep 9, 2019 | Updated on Sep 9, 2019

Here's an analysis of the annual report of CIPLA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY20); Net Profit Up 5.6% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CIPLA has posted a net profit of Rs 5 bn (up 5.6% YoY). Sales on the other hand came in at Rs 40 bn (up 1.3% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (4QFY19); Net Profit Up 144.0% (Quarterly Result Update)

May 24, 2019 | Updated on May 24, 2019

For the quarter ended March 2019, CIPLA has posted a net profit of Rs 4 bn (up 144.0% YoY). Sales on the other hand came in at Rs 44 bn (up 19.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY19); Net Profit Up 17.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, CIPLA has posted a net profit of Rs 3 bn (up 17.5% YoY). Sales on the other hand came in at Rs 40 bn (up 2.4% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Nov 13, 2019 09:53 AM

TRACK CIPLA

COMPARE CIPLA WITH

MARKET STATS